ReviewDrugs & aging2013
Atrial fibrillation in the elderly.
Review in Drugs & aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Risk of dementia in patients with atrial fibrillation: Short versus long follow-up. A systematic review and meta-analysis.International journal of geriatric psychiatry · 2021Pooled it
- Efficacy and Safety of Ablation for Symptomatic Atrial Fibrillation in Elderly Patients: A Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Appropriateness of oral anticoagulant therapy and associated factors among hospitalized atrial fibrillation patients with the CHAeNeurologicalSci · 2026Article
- Atrial Fibrillation Related Coronary Embolism: Diagnosis in the Focus.Journal of personalized medicine · 2023Article
- Comparative Effectiveness and Safety of Oral Anticoagulants by Dementia Status in Older Patients With Atrial Fibrillation.JAMA network open · 2023Article
- Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era.Healthcare (Basel, Switzerland) · 2022Article
- Paroxysmal and Non-Paroxysmal Atrial Fibrillation in Middle Eastern Patients: Clinical Features and the Use of Medications. Analysis of the Jordan Atrial Fibrillation (JoFib) Study.International journal of environmental research and public health · 2022Article
- The in-ear region as a novel anatomical site for ECG signal detection: validation study on healthy volunteers.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2021Article
- Drug interactions of direct oral anticoagulants in elderly patients with cardiometabolic diseases.Current research in pharmacology and drug discovery · 2021Review
- Amiodarone in the aged.Australian prescriber · 2019Review
- Amiodarone-Induced Retinal Neuronal Cell Apoptosis Attenuated by IGF-1 via Counter Regulation of the PI3k/Akt/FoxO3a Pathway.Molecular neurobiology · 2017Article
- Cardiovascular KPathobiology of aging & age related diseases · 2016Review
- Age-associated abnormalities of intrinsic automaticity of sinoatrial nodal cells are linked to deficient cAMP-PKA-Ca(2+) signaling.American journal of physiology. Heart and circulatory physiology · 2014Article
- Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation.Clinical interventions in aging · 2014Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common arrhythmia in older adults with a prevalence of 9 % in adults aged 80 years or older. AF patients have a five times greater risk of developing stroke than the general population. Using anticoagulants for stroke prevention in the elderly becomes a challenge because both stroke and bleeding complications increase with age. CHA₂DS₂-VASc and HAS-BLED scores are currently used as stroke and bleeding risk evaluations. When the HAS-BLED score is 3 or higher, caution and efforts to correct reversible risk factors are advised. Regardless of the HAS-BLED score, warfarin or novel oral anticoagulants are a IIa recommendation for CHA₂DS₂-VASc of 1, except for a score of 1 for females, and a IA recommendation for the score of 2 or higher. Aspirin is no longer recommended for AF thromboprophylaxis. In an elderly patient, lenient rate control is preferred over rhythm control owing to fewer adverse drugs effects and hospitalizations. When rhythm control is needed, dronedarone is a new antiarrhythmic drug that can be considered in patients who have paroxysmal AF and no history of heart failure. Although less efficacious than amiodarone, dronedarone has a fewer thyroid, neurologic, dermatologic, and ocular side effects than amiodarone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.